Aurobindo Pharma Vice-Chairman and Managing Director K Nithyananda Reddy said the company’s second quarter performance was subdued, mainly due to macro-environment factors and higher competitive intensity for some products in the US.
Sebi to review FPI rules, align with global norms
The Securities and Exchange Board of India is set to release a consultation paper aimed at refining compliance requirements for foreign portfolio investors. Chairman Tuhin